Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FRG8701 is a new Histamine H2-receptor antagonist with an IC50 of ranging from 0.25 to 0.43 μM.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
ターゲット&IC50 | H2 receptor:0.25 to 0.43 μM |
In vivo | FRG8701 effectively inhibits the formation of gastric lesions induced by various necrotizing agents, demonstrating its protective effects on the gastrointestinal tract. Oral administration of FRG8701 produces a dose-dependent reduction in the development of gastric lesions caused by stress, indomethacin, and the formation of duodenal ulcers due to mepirizole, with ED50 values ranging from 1.1 to 9.4 mg/kg for gastric lesions and 1.7 to 6.9 mg/kg for each ulcer model. Additionally, in pylorus-ligated rats, intraduodenal delivery of FRG8701 dose-dependently decreases total acid output. Furthermore, FRG8701, whether administered orally or intraperitoneally at doses of 10 or 30 mg/kg, significantly prevents gastric mucosal lesions induced by 0.4 N HCl+50% ethanol, underscoring its potential as a protective agent against gastrointestinal damage. |
分子量 | 418.55 |
分子式 | C22H30N2O4S |
CAS No. | 108498-50-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FRG8701 108498-50-6 GPCR/G Protein Immunology/Inflammation Neuroscience Histamine Receptor FRG 8701 FRG-8701 Inhibitor inhibitor inhibit